Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors. Issue 24 (22nd August 2022)

• Record Type: Journal Article
• Authors: Bernal, Kévin; Touma, Charbel; Erradhouani, Chedi; Boronat‐Belda, Talía; Gaillard, Lucas; Al Kassir, Sara; Le Mentec, Hélène; Martin‐Chouly, Corinne; Podechard, Normand; Lagadic‐Gossmann, Dominique; Langouet, Sophie; Brion, François; Knoll‐Gellida, Anja; Babin, Patrick J.; Sovadinova, Iva; Babica, Pavel; Andreau, Karine; Barouki, Robert; Vondracek, Jan; Alonso‐Magdalena, Paloma; Blanc, Etienne; Kim, Min Ji; Coumoul, Xavier
• Is Part Of: FEBS letters. Volume 596:Issue 24(2022)
• Page Start: 3107
• Page End: 3123
• Publication Date: 2022-08-22
• Subjects: appetite -- bisphenol -- dioxin -- inflammation -- insulin resistance -- microbiota -- perfluorinated compounds -- phthalate -- TBT; Biochemistry -- Periodicals; Biophysics -- Periodicals; Molecular biology -- Periodicals; Biochimie -- Périodiques; Biochemistry; Biophysics; Molecular biology; Periodicals; 572.05
• DOI: 10.1002/1873-3468.14465
• Languages: English
• ISSNs: 0014-5793

Abstract

Abstract : The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic ( in vivo, in vitro and in silico ) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century. Abstract : In this review, we describe endocrine disruptor (ED)‐related alterations in tissues involved in metabolic homeostasis, that is, adipose tissue, liver, pancreas, intestine and brain. We also present epigenetic effects of EDs. Finally, we propose an integrative view of multi‐organ alterations that explain how EDs can contribute to the development of metabolic diseases.